Abstract
A randomized, controlled trial of adjuvant immunochemotherapy with PSK ® (Kureha Chemical Industry Co., Tokyo, Japan) in curatively resected colorectal cancer was studied in 35 institutions in the Kanagawa prefecture. From March 1985 to February 1987, 462 patients were registered. Four hundred forty-eight of those patients (97.0 percent) satisfied the eligibility criteria. The control group received mitomycin C intravenously on the day of and the day after surgery, followed by oral 5-fluorouracil (5-FU) administration for over six months. The PSK ® group received PSK ® orally for over three years, in addition to mitomycin C and 5-FU as in the control group. At the end of February 1990, the median follow-up time for this study was four years (range, three to five years). The disease-free survival curve and the survival curve of the PSK ® group were better than those of the control group, and differences between the two groups were statistically significant (disease-free survival,P =0.013; survival,P =0.013). These results indicate that adjuvant immunochemotherapy with PSK ® was beneficial for curatively resected colorectal cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
SAS Institute Inc. SAS user's guide: statistics. 5th ed. Cary, NC: SAS Institute, 1985.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457–81.
Mantel N. Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163–70.
Buyse M, Zeleniuchi-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: why we still don't know. JAMA 1988;259:3571–8.
Hattori T, Nakajima T, Nakazato H. Postoperative adjuvant immunochemotherapy with Mitomycin C, Tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy. Jpn J Surg 1990;20:127–36.
Mavlight GM, Gutterman JU, Burges MA,et al. Prolongation of postoperative disease-free interval and survival in human colorectal cancer by B.C.G. or B.C.G. plus 5-fluorouracil. Lancet 1976;1:871–5.
Falk RE, MacGregor AB, Landi S,et al. Immunostimulation with intraperitoneally administered Bacille Calamette Guérin for advanced malignant tumors of gastrointestinal tract. Surg Gynecol Obstet 1976;142:363.
Valdivieso M, Bedikian A, Burgess MA,et al. Chemoimmunotherapy of metastatic large bowel cancer. Cancer 1977;40:2731–9.
Windle R, Bell PR, Shaw D. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987;74:569–72.
Laurie JA, Moertel CG, Fleming TR,et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989;7:1447–56.
Moertel CG, Fleming TR, Macdonald JS,et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–8.
Tsukagoshi S, Hashimoto Y, Fujii G,et al. Krestin (PSK). Cancer Treat Rev 1984;11:131–55.
Kamisato JK, Nowakowski M. Morphological and biochemical alterations of macrophages produced by a glycan, PSK. Immunopharmacology 1988:16 89–96.
Hosokawa M, Mizukoshi T, Morikawa K,et al. The therapeutic effects of an immunopotentiator, PS-K, on 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice in combination with the surgical removal of primary sites. Cancer Immunol Immunother 1986;22:181–5.
Mickey DD, Carvalho L, Foulkes K. Combined therapeutic effects of conventional agents and an immunomodulator, PSK, on rat prostatic adenocarcinoma. J Urol 1989;142:1594–8.
Hirose K, Zachariae CO, Oppenheim JJ,et al. Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res 1990;9:475–83.
Kikuchi Y, Kizawa I, Oomori K,et al. Effects of PSK on interleukin-2 production by peripheral lymphocytes of patients with advanced ovarian carcinoma during chemotherapy. Jpn J Cancer Res 1988;79:125–30.
Author information
Authors and Affiliations
Additional information
Dr. Suzuki is deceased.
About this article
Cite this article
Mitomi, T., Tsuchiya, S., Iijima, N. et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK® in curatively resected colorectal cancer. Dis Colon Rectum 35, 123–130 (1992). https://doi.org/10.1007/BF02050666
Issue Date:
DOI: https://doi.org/10.1007/BF02050666